Neuroendocrine Tumor Treatment Market By Drug Class (Everolimus, Sunitinib, Lu-Dotatate, Lanreotide And Octreotide) - Growth, Future Prospects & Competitive Analysis, 2017 – 2025

World Trade Center Health Program 2013 report on monitoring and treatment furnishes the distribution of neuroendocrine neoplasms in the human body which is 67.5% in gastrointestinal tracts and 25.3% in the bronchopulmonary tract. According to the World Health Organization global incidence rate of malignant neuroendocrine tumors is 0.2 per 100,000 persons. The drugs in the phase III clinical trials are developed as molecular targeted therapy which includes Sulfatinib, Vandetanib and Fotemustine. The radiopharmaceutical developed as somatostatin receptor antagonist is 177Lu-edotreotide PRRT.

Drug class segment for the scope of the report neuroendocrine tumor treatment market comprises drugs which are Everolimus, Lu-Dotatate, Sunitinib, Lanreotide and Octreotide. The product pipeline is also covered in the drug class segment highlighting the phase III drugs and tabular representation of phase II and I drugs.

Country cross sectional analysis of the drugs for neuroendocrine tumor treatment are covered in the geography section which is segmented as follows:

• North America
  • U.S.
  • Canada
• Europe
  • U.K.
  • Germany
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Rest of Asia Pacific
• Latin America
  • Mexico
  • Brazil
  • Rest of LATAM
• Middle East and Africa
  • GCC
  • Rest of Middle East and Africa

Company profiles of the eminent players considered for the scope of the report gives important information regarding the existing product portfolio. Recent news coverage gives updates regarding the status of the drugs in pipeline tested for drug efficacy and safety in the clinical trials studies. Competitive landscape gives gist of the competitive nature of key players present in the neuroendocrine tumor treatment market. Top 3 countries and attractive investment proposition data gives industry investors the market trends present in the attractive markets. The market leaders engaged in manufacturing of drugs for the treatment of neuroendocrine tumors are Exelixis, Inc., Advanced Accelerator Applications, Dauntless Pharmaceuticals, Inc., Hutchinson Medipharma Limited, Ispen, Novartis AG, Progenics Pharmaceuticals, Inc. and Tarveda Therapeutics.

Based on drug class, the neuroendocrine tumor treatment market is categorized into:

• mTOR protein inhibitors (Everolimus)
• Tyrosine kinase 3 inhibitors (Sunitinib)
• Somatostatin receptor antagonists (Lu-Dotatate)
• Growth hormone releasing factor antagonists (Lanreotide)
• Somatostatin receptor agonists (Octreotide)
• Pipeline Analysis
  • Phase III Drugs
    • Vandetanib
    • Fotemustine and Ipilimumab
    • 177Lu-edotreotide PRRT
    • Sulfatinib
  • Tabular Representation of Phase II and I drugs

The clinical manifestation of neuroendocrine tumor suggests that it is benign and sometimes malignant. It is asymptomatic in nature and usually occurs in the gastrointestinal tracts, pancreas, lungs and other parts of the body. The drug therapy employed for the treatment of neuroendocrine tumor consists of targeted drug therapy and somatostatin analogues. Targeted drug therapy comprises of molecules such as Everolimus and Sunitinib. They are gaining demand in the neuroendocrine tumor treatment as they are specifically blocking the growth of cancer by interfering with specific molecules that are engaged in the spread of cancer.

The advantages of targeted drug therapy is that it has fewer side effects in comparison to chemotherapy drugs and suitable for long term treatment of chronic conditions. Somatostatin analogues such as Lu-Dotatate and Octreotide represent a futuristic trend in the treatment of neuroendocrine tumors. They are considered as a viable options for patients resistant to surgery and radiation therapy. The prominent players in neuroendocrine tumor treatment market are Advanced Accelerator Applications, Dauntless Pharmaceuticals, Inc., Exelixis, Inc., Hutchinson Medipharma Limited, Ispen, Novartis AG, Progenics Pharmaceuticals, Inc. and Tarveda Therapeutics.

For the purpose of this study, the global neuroendocrine tumor treatment market is categorized into the following regional and country specific markets:

• North America
  • United States
  • Canada
• Europe
  • United Kingdom
  • Germany
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • GCC
  • Rest of Middle East and Africa

Center for Disease Control and Prevention 2013 report has stated that the incidence rate of gastrointestinal neuroendocrine neoplasms in United States population is 1.4 cases per 100,000 persons. The well-developed diagnostic centers are able to detect asymptomatic neuroendocrine tumors and expedited drug clearance by USFDA contributes to the authority of neuroendocrine tumor treatment drugs market in North America. 

Europe market is influenced by the increasing number of patients suffering with pancreatic neuroendocrine tumors and supportive regulatory environment provided by European Medical Agency to drugs utilized for neuroendocrine tumors treatment.  Asia Pacific Neuroendocrine Tumor Society 2017 report states that the incidence rate of neuroendocrine tumors in Asian Pacific population to be around 1.51 per 100,000 persons. Increasing number of cancer treatment centers providing effective diagnosis and treatment are set to propel the Asia Pacific drugs for of neuroendocrine tumors treatment market.